Grabau D
Department of Pathology, Pathologic/Cytologic Clinic, University Hospital of Lund, 221 85 Lund, Sweden.
Surg Oncol. 2008 Sep;17(3):211-7. doi: 10.1016/j.suronc.2008.04.006. Epub 2008 May 23.
Women with breast cancer and micrometastases only constitute a treatment dilemma. If only a micrometastasis is found in a sentinel lymph node, an axillary lymph node dissection may be considered to be overtreatment and perhaps could be avoided. However, studies have shown decreased survival in patients with micrometastases only. This paper focuses on the pathological work-up behind the classification of breast cancer patients having micrometastases only and on the most recent literature concerning prognosis for breast cancer patients with micrometastases. The goal was to determine if studies to date have been able to define a population of breast cancer patients with micrometastases where the size of the metastasis could indicate whether an axillary lymph node dissection should be undertaken. Tailored surgical treatment of breast cancer patients with micrometastases only is not possible at the present time, due to lack of standardization in the pathological work-up of lymph nodes, which implies that this group of breast cancer patients cannot be delimited with sufficient precision. Tailored systemic therapy is also impossible due to lack of a precisely defined target for a feasible therapy.
仅患有乳腺癌和微转移的女性构成了一个治疗难题。如果在前哨淋巴结中仅发现一个微转移灶,腋窝淋巴结清扫术可能被视为过度治疗,或许可以避免。然而,研究表明仅患有微转移灶的患者生存率会降低。本文聚焦于仅患有微转移灶的乳腺癌患者分类背后的病理检查,以及有关仅患有微转移灶的乳腺癌患者预后的最新文献。目的是确定迄今为止的研究是否能够界定出这样一群仅患有微转移灶的乳腺癌患者,即转移灶的大小能够表明是否应该进行腋窝淋巴结清扫术。目前,由于淋巴结病理检查缺乏标准化,仅患有微转移灶的乳腺癌患者无法进行个体化手术治疗,这意味着无法足够精确地界定这组乳腺癌患者。由于缺乏可行治疗的精确界定靶点,个体化全身治疗也无法实现。